{"id":12116,"date":"2022-06-07T10:04:50","date_gmt":"2022-06-07T10:04:50","guid":{"rendered":"http:\/\/cvx.vc\/?p=12116"},"modified":"2022-06-07T10:04:50","modified_gmt":"2022-06-07T10:04:50","slug":"dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital","status":"publish","type":"post","link":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/","title":{"rendered":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital"},"content":{"rendered":"\n

BioTech-virksomheden Scandion Oncology planl\u00e6gger at opnotere fra den svenske First North-b\u00f8rs til Nasdaqs hovedb\u00f8rs med ambitionen om at rejse 67 mio. kr. Scandion Oncology udvikler l\u00e6gemidler, der specifikt er rettet mod kemoterapiresistensmekanismer. Scandion Oncology fokuserer p\u00e5 forbedring af resultatet og livskvaliteten for kr\u00e6ftpatienter.<\/p>\n\n\n\n

\u00bbVi er glade for at kunne rejse yderligere kapital til at finansiere vores langsigtede planl\u00e6gning og eksekvering af vores strategi. P\u00e5 den m\u00e5de kan vi skabe mest v\u00e6rdi af vores forbindelser, f\u00f8rst og fremmest ved at ca. fordoble det kommercielle potentiale for SCO-101. Dette vil v\u00e6re et meget vigtigt element i vores langsigtede v\u00e6rdiskabelse,\u00ab<\/em> udtaler Bo Rode Hansen, Adm. direkt\u00f8r af Scandion Oncology, i en pressemeddelelse.<\/p>\n\n\n\n

Scandion Oncology blev stiftet i 2017 af Jan Stenvang og besk\u00e6ftiger i dag 19 medarbejdere. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.<\/p>\n\n\n\n

L\u00e6s hele artiklen p\u00e5 KapWatch her<\/em><\/strong><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.<\/p>\n","protected":false},"author":25,"featured_media":12117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"yoast_head":"\nDansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital | CVX Ventures<\/title>\n<meta name=\"description\" content=\"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\" \/>\n<meta property=\"og:locale\" content=\"da_DK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital\" \/>\n<meta property=\"og:description\" content=\"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\" \/>\n<meta property=\"og:site_name\" content=\"CVX Ventures\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cvxventures\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-07T10:04:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"615\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Jessica Axholt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet af\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Jessica Axholt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimeret l\u00e6setid\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\"},\"author\":{\"name\":\"Kim Jessica Axholt\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\"},\"headline\":\"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital\",\"datePublished\":\"2022-06-07T10:04:50+00:00\",\"dateModified\":\"2022-06-07T10:04:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg\",\"articleSection\":[\"Blogindl\u00e6g\"],\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\",\"url\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\",\"name\":\"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital | CVX Ventures\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg\",\"datePublished\":\"2022-06-07T10:04:50+00:00\",\"dateModified\":\"2022-06-07T10:04:50+00:00\",\"description\":\"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#breadcrumb\"},\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg\",\"width\":1024,\"height\":615},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/cvx.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvx.vc\/da\/#website\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"name\":\"CVX Ventures\",\"description\":\"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder\",\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvx.vc\/da\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"da-DK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cvx.vc\/da\/#organization\",\"name\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"width\":827,\"height\":394,\"caption\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/cvxventures\/\",\"https:\/\/www.linkedin.com\/company\/cvxventures\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\",\"name\":\"Kim Jessica Axholt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"caption\":\"Kim Jessica Axholt\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital | CVX Ventures","description":"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/","og_locale":"da_DK","og_type":"article","og_title":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital","og_description":"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.","og_url":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/","og_site_name":"CVX Ventures","article_publisher":"https:\/\/www.facebook.com\/cvxventures\/","article_published_time":"2022-06-07T10:04:50+00:00","og_image":[{"width":1024,"height":615,"url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg","type":"image\/jpeg"}],"author":"Kim Jessica Axholt","twitter_card":"summary_large_image","twitter_misc":{"Skrevet af":"Kim Jessica Axholt","Estimeret l\u00e6setid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#article","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/"},"author":{"name":"Kim Jessica Axholt","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb"},"headline":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital","datePublished":"2022-06-07T10:04:50+00:00","dateModified":"2022-06-07T10:04:50+00:00","mainEntityOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg","articleSection":["Blogindl\u00e6g"],"inLanguage":"da-DK","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/","url":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/","name":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital | CVX Ventures","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg","datePublished":"2022-06-07T10:04:50+00:00","dateModified":"2022-06-07T10:04:50+00:00","description":"BioTech-virksomheden Scandion Oncology planl\u00e6gger en b\u00f8rsnotering med m\u00e5let om at rejse 67 mio. kr. Virksomheden vil bruge bruge den nye kapital til at udvide de kliniske studier ved l\u00e6gemiddelkandidaten mod metastatisk kemoresistent tarmcancer.","breadcrumb":{"@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#breadcrumb"},"inLanguage":"da-DK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/"]}]},{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#primaryimage","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/06\/Bo-Rode-Hansen-Colour-1024x615-1.jpg","width":1024,"height":615},{"@type":"BreadcrumbList","@id":"https:\/\/cvx.vc\/da\/insights\/dansk-biotech-selskab-vil-skifte-boers-i-nyt-forsoeg-paa-at-hente-kapital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/cvx.vc\/"},{"@type":"ListItem","position":2,"name":"Dansk BioTech-selskab vil skifte b\u00f8rs i nyt fors\u00f8g p\u00e5 at hente kapital"}]},{"@type":"WebSite","@id":"https:\/\/cvx.vc\/da\/#website","url":"https:\/\/cvx.vc\/da\/","name":"CVX Ventures","description":"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder","publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvx.vc\/da\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"da-DK"},{"@type":"Organization","@id":"https:\/\/cvx.vc\/da\/#organization","name":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor","url":"https:\/\/cvx.vc\/da\/","logo":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","width":827,"height":394,"caption":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor"},"image":{"@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cvxventures\/","https:\/\/www.linkedin.com\/company\/cvxventures\/"]},{"@type":"Person","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb","name":"Kim Jessica Axholt","image":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","caption":"Kim Jessica Axholt"}}]}},"_links":{"self":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/12116"}],"collection":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/comments?post=12116"}],"version-history":[{"count":0,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/12116\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media\/12117"}],"wp:attachment":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media?parent=12116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/categories?post=12116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/tags?post=12116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}